Boehringer Ingelheim, Lilly expand collaboration to focus on Jardiance
Boehringer Ingelheim and Eli Lilly have been developing and commercialising Trajenta (linagliptin) and Basaglar (insulin glargine)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Nov 19
Boehringer Ingelheim and Eli Lilly have been developing and commercialising Trajenta (linagliptin) and Basaglar (insulin glargine)
The new tests are expected to provide a cost-effective alternative to current genomic cancer trials, says the University…
05 Nov 19
GE has rolled out Clariscan in 10ml, 15ml and 20ml single-dose vials, packaged with a 2D data matrix…
As part of the Nvidia Inception Program, the UK start-up has used AI to help pathologists classify and…
04 Nov 19
Automated Medical Systems is a Georgia-based healthcare IT company that serves clients in Florida, Georgia, Tennessee, Texas and…
01 Nov 19
Medtronic has designed the low-profile Valiant Navion system based on the existing Valiant Captivia thoracic stent graft system
Swedish start-up Flow's headset uses brain-stimulation to influence low neural activity in the organ that's thought to cause…
31 Oct 19
The collaboration combines Pandion’s modular biologics and functional immunology expertise with Astellas' advanced therapeutics development and global commercialisation…
30 Oct 19
The EC approval is based on data from the Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy…
Pharmeum CEO Zain Rana believes blockchain could realise its potential best in the healthcare industry by making patient…